ライフサイエンスコーパス: corneal scar

1 bliteration of vessels with stabilization of corneal scar.

2 ncluding corneal erosion, corneal ulcers, or corneal scars.

3 one of the alternatives for the treatment of corneal scars.

4 ages, 3 had post-herpetic leukoma, and 5 had corneal scars.

5 with postinfectious, full-thickness, central corneal scars.

6 source of fibrotic tissue in nontransparent corneal scars.

7 including steroids, have been used to treat corneal scarring.

8 h persistent visual impairment due to severe corneal scarring.

9 t virus that can cause recurrent disease and corneal scarring.

10 active outcome while eliminating or reducing corneal scarring.

11 n, PAI-1R may be a useful agent in combating corneal scarring.

12 ation of vision in patients with significant corneal scarring.

13 surgery, recent rigid contact lens wear, and corneal scarring.

14 ology and for cell-based therapies targeting corneal scarring.

15 anglion and reduced herpetic blepharitis and corneal scarring.

16 action may be an important goal for reducing corneal scarring.

17 ly protected against HSV-1-induced death and corneal scarring.

18 rimary genes involved in the pathobiology of corneal scarring.

19 nse leading to exacerbation of HSV-1-induced corneal scarring.

20 ice are normally refractory to HSV-1-induced corneal scarring.

21 spite the fact that KOS normally produces no corneal scarring.

22 te or severe vision loss, primarily owing to corneal scarring.

23 l decompensation from increased IOP (3), and corneal scar (1) underwent combined endoscopic vitrectom

24 included partial-thickness anterior stromal corneal scars (15 eyes), Descemet membrane ruptures (6 e

25 causes of vision loss were cataract (19.7%), corneal scars (15.7%), refractive error and amblyopia (1

26 Main diagnoses were corneal scar (22.9%), limbal dermoid (21.9%), anterior s

27 eal neovascularization (44%), dry eye (38%), corneal scarring (26%), ectropion (25%), blepharitis (23

28 0.13 years; indications for PK were herpetic corneal scar (53.3%), corneal stromal dystrophy (23.3%),

29 or keratoconus (8), microbial keratitis (6), corneal scar (6), corneal keloid (3), chemical injury wi

30 ) patients; the most common complication was corneal scarring (70%).

31 Causes of loss of vision included corneal scarring (94.0%), corneal perforation (4.8%), an

32 from in vivo experiments suggest that in old corneal scars, a nonkeratocyte phenotype persists in an

33 s for MK in high-risk, vascularized herpetic corneal scars achieves clinical outcomes that remain sta

34 ggests that limiting TGFss system may reduce corneal scarring after excimer laser ablation.

35 ltrates is more than that resulting from the corneal scarring after healing.

36 s to naive mice, resulted in exacerbation of corneal scarring after HSV-1 challenge (P < 0.0001).

37 dividually to naive mice, and the affects on corneal scarring after HSV-1 challenge were determined.

38 atitis can cause serious problems, including corneal scar and perforation, which can cause vision los

39 -nine percent of patients with keratitis had corneal scarring and 26% had vision of 20/40 or worse at

40 Corneal scarring and blindness are consequences of the i

41 ocular infections caused by HSV-1 can cause corneal scarring and blindness.

42 ar infections, which is the leading cause of corneal scarring and blindness.

43 MPXROD may result in corneal scarring and blindness.

44 lammatory response that leads to progressive corneal scarring and blindness.

45 , can lead to infection, corneal neuropathy, corneal scarring and impaired vision.

46 hlight the most important causes of acquired corneal scarring and infiltrates in children.

47 The converse was true for corneal scarring and phthisis (14.0% and 27.3%, respecti

48 Corneal scarring and severe inflammation at baseline wer

49 dophakic bullous keratopathy, postinfectious corneal scarring and thinning and keratoconus were the m

50 he patient had already developed significant corneal scarring and visual debilitation by the time top

51 If extensive corneal scarring and/or limbal stem cell deficiency are

52 D), Ninth and Tenth Revisions, codes of 371 (corneal scar) and H17 (corneal opacity), respectively.

53 , virus replication in the eye, blepharitis, corneal scarring, and dermatitis were determined.

54 plication in the eye, survival, blepharitis, corneal scarring, and latency were determined.

55 ial basement membrane dystrophy, superficial corneal scars, and previous radial keratotomy will have

56 ce interval [CI]: 2.61-59.99; P = 0.002) and corneal scarring (aOR: 3.06; 95% CI, 1.15-8.14; P = 0.02

57 Current treatment options for controlling corneal scarring are limited, and outcomes are typically

58 lindness and visual impairment, particularly corneal scarring as a result of vitamin A deficiency, co

59 able refractive outcomes in the treatment of corneal scarring associated with Bowman layer irregulari

60 The charts of 22 patients with anterior corneal scarring associated with irregularities in the B

61 leusis and decreasing postoperative pain and corneal scarring associated with PRK.

62 s well as a sharply defined anterior-stromal corneal scar at both eyes.

63 urrent disease, including stromal keratitis, corneal scarring, blindness, and encephalitis.

64 susceptible to exacerbation of HSV-1-induced corneal scarring by gK vaccination (P < 0.0001).

65 iece microkeratome-assisted MK for traumatic corneal scars can allow excellent visual rehabilitation

66 ra copies of glycoprotein K (gK) exacerbated corneal scarring (CS) in mice.

67 pe 1 (HSV-1) glycoprotein K (gK) exacerbated corneal scarring (CS) in ocularly infected mice.

68 Indeed, a major cause of corneal scarring (CS) is the scarring induced by HSV-1 f

69 ected mouse strains had significantly higher corneal scarring (CS) than did McKrae-infected mice.

70 in KOS or McKrae, and the relative amount of corneal scarring determined 28 days after challenge.

71 Corneal scarring/fibrosis in rabbit eyes was induced by

72 (n = 15), corneal perforation (n = 11), and corneal scar following treated infectious keratitis (n =

73 ta support the hypothesis that CTGF promotes corneal scar formation and imply that regulating CTGF sy

74 have important implications in regulation of corneal scar formation.

75 brane pemphigoid presenting with HR-EOMs and corneal scarring has an increased risk of stage progress

76 overexpression of CD80 by HSV-1 exacerbated corneal scarring in BALB/c mice.

77 ges did not alter the HSV-1-induced death or corneal scarring in immunized mice.

78 of mice with a recombinant HSV-1 exacerbated corneal scarring in infected mice.

79 mice during acute infection and caused more corneal scarring in latently infected rabbits.

80 Here, we demonstrate increased latency and corneal scarring in LTalpha(-/-) infected mice, independ

81 ls, increased 50% lethal dose, and decreased corneal scarring in ocularly infected mice compared to t

82 Fifty-three percent had corneal scarring in one or both eyes.

83 related with higher 50% lethal dose and less corneal scarring in vivo.

84 glycan expression pattern similar to that of corneal scars in vivo.

85 t pachymetry, corneal transplantation rates, corneal scarring incidence, and patient-reported outcome

86 Corneal scarring is caused by the host immune response t

87 However, the ability of steroids to reduce corneal scarring is limited and associated with numerous

88 Corneal scarring is the third leading cause of global bl

89 of virus replication in the eyes, levels of corneal scarring, latency-reactivation in the trigeminal

90 Vision loss in children is from corneal scarring leading to deprivation and/or refractiv

91 expression of CD80 has a detrimental role in corneal scarring, likely by increasing CD8(+) T cell rec

92 herpetic episodes is high, and the resultant corneal scarring may require penetrating keratoplasty fo

93 e that with the addition of TGF-beta1, a 3-D corneal scar model can be generated.

94 s, including moderate or severe vision loss, corneal scarring, neurotrophic keratitis, band keratopat

95 Gonococcal ophthalmia neonatorum can cause corneal scarring, ocular perforation, and blindness as e

96 ficant corneal irregularities and/or central corneal scarring often secondary to long-standing preope

97 elate with any subset of BKC diagnoses (e.g. corneal scar or ulcer, chalazion, marginal or superficia

98 The most important causes of corneal scarring or infiltrates in children are keratoco

99 ervous system involvement, acral mutilation, corneal scarring or ulceration, liver failure, and metab

100 eal involvement without scarring), moderate (corneal scarring), or severe (corneal scarring with thin

101 Corneal scars originate from keratocyte-derived fibrobla

102 The presence of corneal scarring (P < .00001; OR: 3.00), corneal ulcerat

103 cinated C57BL/6 mice resulted in significant corneal scarring (P < 0.0001), despite the fact that C57

104 ccinated BALB/c mice resulted in significant corneal scarring (P = 0.0003), despite the fact that KOS

105 conjunctival corkscrew vessels (P < 0.001), corneal scarring (P = 0.01) and pingueculae under the ag

106 ous corneal disorders including keratoconus, corneal scarring, post-corneal transplant, and post-refr

107 oblasts could be important in regulating the corneal scarring process.

108 ands, irregularity of the eyelid margin, and corneal scarring remained for the patient.

109 How anti-gK IgG exacerbated HSV-1 induced corneal scarring remains to be determined.

110 d LTalpha(-/-) mice had significantly higher corneal scarring than WT mice, and adoptive T cell trans

111 er study, 41 consecutive eyes with traumatic corneal scars that underwent 2-piece microkeratome-assis

112 In case 1 (corneal scarring) the OCT images helped to guide manual

113 ntibody titers (approximately 1:800-1:1200), corneal scarring (trace) and survival (100%) were simila

114 ailed previous graft (five eyes, 22.7%), and corneal scarring (two eyes, 9.1%).

115 s with vascularized (>=2 quadrants) herpetic corneal scars underwent 2-piece microkeratome-assisted M

116 5 (AAV5)-mediated Id3 gene therapy to treat corneal scarring using an established rabbit in vivo dis

117 Presence of residual corneal scarring, visual acuity at the last visit, chang

118 Its main outcome measures are corneal scarring, visual acuity, keratometry, and qualit

119 ith corneal hydrops, whereas the presence of corneal scarring was a preventive factor.

120 Baseline corneal scarring was a risk factor for relapse (adjusted

121 Corneal scarring was induced by mechanically removing th

122 f gK vaccination to exacerbate HSV-1-induced corneal scarring was not mouse strain or HSV-1 strain sp

123 Central corneal scarring was present in 1436 (33%) eyes.

124 The gK-induced exacerbation of corneal scarring was related to anti-gK IgG.

125 Corneal scarring, whether caused by trauma, laser refrac

126 ng), moderate (corneal scarring), or severe (corneal scarring with thinning or perforation) disease b